. 170: [5385][5386][5387][5388] 1988). To investigate the role of His-426 in enzymatic activity, oligonucleotide-directed mutagenesis was used to construct mutant proteins encoding Ala, Glu, Gly, Lys, or Pro at position 426. The effect of these amino acid substitutions on ADP-ribosyltransferase activity was analyzed in 34,000-Da carboxy-terminal exotoxin A peptides (H426n peptides). ADP-ribosyltransferase activity of the H426n peptides fell within a range between 0.002 and 28% of wild-type levels of activity, suggesting that His-426 is required for full expression of enzymatic activity of exotoxin A. To investigate a possible catalytic function of His-426, the abilities of full-size (66,000-Da) wild-type exotoxin A and mutant proteins encoding either Ala-426 or Tyr-426 to hydrolyze NAD were compared by measuring NAD-glycohydrolase activity. This analysis revealed that exotoxin A encoding either Ala-426 or Tyr-426 expressed < 1% of wild-type levels of NAD-glycohydrolase activity. Several criteria, including differential enzymatic activation properties and unique tryptic digestion patterns, revealed that the wild-type and mutant full-size proteins exhibit conformational differences. Our data suggest that His-426 plays a critical structural role in establishing the molecular architecture of the catalytic site in domain III and is important in orienting active-site residues in the cleft.
To investigate the role of His-426 in enzymatic activity, oligonucleotide-directed mutagenesis was used to construct mutant proteins encoding Ala, Glu, Gly, Lys, or Pro at position 426. The effect of these amino acid substitutions on ADP-ribosyltransferase activity was analyzed in 34,000-Da carboxy-terminal exotoxin A peptides (H426n peptides). ADP-ribosyltransferase activity of the H426n peptides fell within a range between 0.002 and 28% of wild-type levels of activity, suggesting that His-426 is required for full expression of enzymatic activity of exotoxin A. To investigate a possible catalytic function of His-426, the abilities of full-size (66,000-Da) wild-type exotoxin A and mutant proteins encoding either Ala-426 or Tyr-426 to hydrolyze NAD were compared by measuring NAD-glycohydrolase activity. This analysis revealed that exotoxin A encoding either Ala-426 or Tyr-426 expressed < 1% of wild-type levels of NAD-glycohydrolase activity. Several criteria, including differential enzymatic activation properties and unique tryptic digestion patterns, revealed that the wild-type and mutant full-size proteins exhibit conformational differences. Our data suggest that His-426 plays a critical structural role in establishing the molecular architecture of the catalytic site in domain III and is important in orienting active-site residues in the cleft.
Exotoxin A (ETA) is an extracellular ADP-ribosylating toxin produced by the opportunistic pathogen Pseudomonas aeruginosa (24, 32) . ETA is cytocidal to many cultured cell lines and is toxic to several animal species (38, 39) . The toxic nature of ETA is due to its ability to halt protein synthesis at the level of polypeptide chain elongation by catalyzing ADP-ribosylation of eukaryotic elongation factor 2 (EF2) (23, 24, 39) . A related enzymatic activity of ETA is NADglycohydrolase activity. The slow hydrolysis of NAD, which releases ADP-ribose and nicotinamide, can be measured by incubating ETA with NAD in the absence of the target protein EF2 (10, 31) .
ETA is secreted from P. aeruginosa as an inactive proenzyme which must undergo structural alteration for either ADP-ribosyltransferase activity or NAD-glycohydrolase activity to be expressed (10, 31, 33, 41) . One way ETA can be treated to express enzymatic activity in vitro is to preincubate the proenzyme with a denaturing agent and a reducing agent. This results in a nontoxic, full-size, enzymatically active form of the protein. An alternate way to activate ETA to express enzymatic activity is to physically separate the amino-terminal binding portion of ETA and the carboxyterminal enzymatic portion of the protein by using methods such as proteolysis or freeze-thaw cycles.
The crystalline structure of the ETA proenzyme has been solved (1) . In addition, the ETA structural gene, toxA, has been cloned and sequenced (18) . The availability of these data allowed Allured and coworkers (1) to propose a molecular model for the proenzyme form of ETA. Their model reveals that ETA has three structural domains. The aminoterminal domain I has been shown to be involved in eukary-otic cell recognition (8, 19, 26) . The central domain II is required for cytotoxicity of ETA (22, 40) and may be involved in the translocation function of the protein (27) . The carboxy-terminal domain III is the enzymatic portion of the protein (18, 22) . Specifically, residues 400 to 603 are required for full expression of enzymatic activity (7, 40) . Domain III has a cleft which is proposed to be the enzyme active site (1) . Experimental evidence supports the role of the identified cleft as the catalytic center of domain III. In particular, Glu-553 has been identified as an active-site residue which is the nicotinamide subsite of NAD binding (6) . Several other domain III residues located in the cleft region, including Arg-458, Arg-467, and Trp-466, have been proposed to interact with NAD (4, 13) , while Tyr-481 has been hypothesized to interact with EF2 (35) .
Another domain III residue, His-426, has been implicated as having a catalytic role in ETA (43, 44) . This residue was identified by genetic analysis of the toxAl gene cloned from P. aeruginosa PAO-PR1. This mutant strain produces a nontoxic, enzymatically inactive, full-size ETA protein called CRM 66 (12) . Nucleotide sequence analysis of tox4l revealed that CRM 66 encodes tyrosine at position 426, whereas the wild-type ETA protein has histidine at this position (43) . The histidine-to-tyrosine substitution in CRM 66 results in loss of 90% of the ADP-ribosyltransferase activity of wild-type ETA (43) . It was also demonstrated that expression of enzymatic activity of CRM 66 does not require treatment with a denaturing agent and a reducing agent, whereas this process is required for expression of enzymatic activity from the wild-type protein (43) . The differential response of the wild-type and mutant ETA proteins to in vitro activation of enzymatic activity suggested that the conformation of CRM 66 differs from that of the wild-type protein (43) .
Analysis of the molecular model of ETA reveals that His-426 is located within an alpha-helix composed of domain To construct enzymatically active carboxy-terminal clones with amino acid substitutions at position 426, we used the following strategy (Fig. 1) . RF (3) . After culture density reached an optical density of -1.6 at 595 nm, cells were harvested and cell pellets were washed as described by Douglas and Collier (14) . The cell pellet from a 10-ml culture was resuspended in 2. Quantitation of ETA-related protein in E. coli cell lysates. ETA cross-reactive protein present in E. coli extracts was quantitated based on the dot immunobinding method of Jahn et al. (25) . Cell lysates containing H426n peptides were adjusted to a total protein content of 0.5 mg/ml and were serially diluted in 50 mM Tris (pH 7.4). Several dilutions of each lysate were applied to nitrocellulose with a 96-well filtration manifold (Schleicher & Schuell, Inc., Keene, N.H.). A known quantity of purified ETA was diluted in a TB1/pUC9 lysate in the same manner to use as the standard. After application of the samples, the nitrocellulose was processed as described below for Western blots (immunoblots). Dot blots were exposed to Kodak XAR-5 film. One-centimeter squares corresponding to the applied samples were cut from the nitrocellulose, and the amount of radioactivity was quantitated in a gamma counter. The quantity of ETA cross-reactive material in each E. coli lysate was determined from a standard curve of purified ETA diluted in TB1/pUC9 lysate.
Construction and purification of full-size ETA proteins. Full-length forms of the toxA gene with a defined amino acid substitution at position 426 were constructed in the following manner (Fig. 2) . The 700-bp SacII-EcoRI fragment encoding amino acids 413 to 613 of ETA was deleted from pMS1511.8, a broad-host-range plasmid containing a wild-type toxA gene (34, 37) . pPEPH426A and pPEPH426Y were digested with SaclI and EcoRI, and the 700-bp SacII-EcoRI fragment encoding residues 413 to 613 was isolated after agarose gel electrophoresis. Each isolated fragment was ligated into pMS1511.8 from which the corresponding SacII-EcoRI fragment was deleted (Fig. 2) . The resultant plasmids, pTOXH426A and pTOXH426Y, contain a toxA gene encoding full-size ETA (66,000 Da) with Ala or Tyr, respectively, at position 426 on a broad-host-range plasmid. Ampicillinresistant E. coli transformants were screened for the presence of the toxA insert by restriction endonuclease analysis of isolated plasmid DNA. Plasmids encoding full-length ETA proteins were transformed into the toxA mutant P. aeruginosa PA103toxAQ by the method of Olsen et al. (37) . PA103toxAfQ contains an insertionally inactivated chromosomal toexA gene and produces no detectable ETA protein (46) . PA103toxAfQ transformants were selected on minimal medium supplemented with carbenicillin (400 ,ug ml-') and streptomycin (500 ,g ml-').
P. aeruginosa strains were grown for maximal ETA production at 32°C in tryptic soy broth dialysate medium (36) containing carbenicillin (400 ,ug ml-'). ETAH426A and ETAH426Y were purified from the culture supernatant of PA103toxAfQ containing pTOXH426A and pTOXH426Y, respectively. To maximize production of wild-type ETA, culture supematant from the hyper-toxin-producing strain PA103 (32) containing multiple copies of the toxA positive regulatory locus in pDF191. 8-202 (16) was the source of this protein. ETA was purified from culture supernatant as described by Chaudry et al. (8) . Fractions from column purification steps were analyzed for wild-type ETA by assaying for ADP-ribosyltransferase activity, while fractions containing ETAH426A and ETAH426Y were detected by the dot immunobinding technique. Purity of ETA preparations was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described below.
The quantity of ETA in the purified preparations was determined by analyzing the total protein content of each preparation. The quantity of the contaminating 97-kDa protein in the ETAH426A preparation was determined by densitometer scan analysis. The percentage of the contaminating protein was subtracted from the total protein concentration to get an accurate estimate of the quantity of ETAH426A. This corrected concentration for ETAH426A was used in all subsequent calculations. Approximately 2 mg of wild-type ETA was purified from the culture supernatant of a 150-ml culture of PA103/pDF191. . Approximately 0.7 mg of ETAH426A and 0.5 mg of ETAH426Y were purified from the culture supernatants of 150-ml cultures of PA103toxAfl/pTOXH426A and PA103toxAQ/pTOXH426Y, respectively. SDS-PAGE and Western blot analysis. SDS-polyacrylamide gels were prepared by the method of Laemmli (30) . Proteins were transferred to nitrocellulose for Western blot analysis as described by Burnette (5) . Nitrocellulose was blocked with 5% BLOTTO (28) . Antibody specific for ETA was prepared by immunizing rabbits with ETA excised from a gel after SDS-PAGE of commercially available ETA (Swiss Serum and Vaccine Institute, Beme, Switzerland). Incubation of nitrocellulose with primary antibody was followed by incubation with 1251I-protein A and exposure to X-ray film.
ADP-ribosyltransferase activity of purified full-size ETA proteins. To determine the response of ADP-ribosyltransferase activity of each purified toxin preparation to urea plus DTT treatment, we performed assays on ETA that was either treated (preincubated in 4 M urea plus 65 mM DTT) or untreated (preincubated in 50 mM Tris-HCl [pH 7.4]) for 15 min at 25°C. After the preincubation step, assays were diluted 1:7.5 into reaction mixtures described above. Thus, the assay conditions used to analyze the purified toxins were identical to those used for the H426n peptides. Assays were performed at 25°C for 10 min with 0. 15 Assays were performed at 37°C for the times specified below. After incubation, assays were stopped and free nicotinamide was quantitated as described by Cortina and Barbieri (11) .
Once the urea plus DTT treatment response was determined, NAD-glycohydrolase activity was quantitated by using the most active form of each toxin (treated wild-type ETA, untreated ETAH426A, and untreated ETAH426Y (Table 2) . Typically, DNA sequence analysis of three plaque-purified clones obtained from the mutagenesis procedure revealed that two clones contained the desired mutation.
Examination of the enzymatic activity of H426n peptides allowed both the structural and catalytic roles of His-426 to be examined. Substitution of Tyr-426 with Ala, Glu, or Lys should retain the integrity of the alpha-helix containing residue 426 (9) . These substitutions would test the effect of an uncharged, a negatively charged, and a positively charged residue, respectively, on enzymatic activity. Perturbation of the helix by introduction of the helix-breaking residue Gly or Pro (9) would test whether the integrity of this alpha-helix is important for expression of enzymatic activity.
Properties of H426n mutations in ETA peptides. Analyzing mutant carboxy-terminal H426n peptides provided the advantage of characterizing the effect of amino acid substitutions on enzymatic activity with the least influence of the remainder of ETA on the catalytic properties of the protein.
The fragment of ETA used as the template for oligonucleotide-directed mutagenesis encodes a peptide (residues 308 to 493) that is insufficient to express enzymatic activity (22, 40) . Consequently, the toxA fragments with confirmed amino acid substitutions at residue 426 were manipulated to create carboxy-terminal peptides capable of expressing enzymatic activity (Fig. 1) . Ligation of the 1,012-bp HincII-EcoRI fragment from the RF DNA containing a defined substitution into SmaI-and EcoRI-digested pUC9 creates an in-frame fusion of the carboxy-terminal 305 amino acids of ETA with the first 15 amino acids encoded by the pUC9 multiple cloning site. To peptides by Western blot analysis of E. coli whole-cell lysates (Fig. 3) . A single E. coli clone expressing each of the H426n peptides was chosen for further analysis.
The calculated molecular mass of the 305-amino-acid H426n peptide is 32,444 Da. When the molecular mass from fusion of the 15 amino acids of the pUC9 vector is included (1,615 Da), the predicted molecular mass of the ETA fusion peptide is 34,059 Da. Western blot analysis of E. coli lysates expressing the H426n peptides revealed a single major band migrating at approximately 36,000 Da on SDS-polyacrylamide gels (Fig. 3) . This is in close agreement with the predicted molecular mass of 34,059 Da. The lysates prepared from E. coli expressing each of the H426n peptides exhibited a similar pattern of minor bands migrating below the major ETA cross-reactive band (Fig. 3) . This suggests that the H426n peptides exhibit similar susceptibility to degradation by proteases endogenous to E. coli. Quantitation of the H426n peptides by the dot immunobinding assay revealed that ETA cross-reactive material composes -1% of the total cellular protein. This value is similar to that reported for expression of the full-size form of ETA in E. coli (14) .
ADP-ribosyltransferase activity in E. coli lysates expressing each of the H426n peptides revealed that regardless of which amino acid was encoded at position 426, ADP-ribosyltransferase activity was not potentiated by urea plus DTT treatment (data not shown). Quantitation of ADP-ribosyltransferase activity in E. coli lysates expressing the H426n peptides is summarized in Table 3 . The specific ADPribosyltransferase activity of the mutant H426n peptides was reduced to a level between 28 and 0.002% of the activity of the wild-type His-426 peptide ( b The specific ADP-ribosyltransferase activity of each H426n peptide is indicated ± the standard error of the mean at the 95% confidence level. The specific activities were determined by calculating the slope of a line representing picomoles of ADP-ribosylated EF2 (ADPR-EF2) formed per microgram of ETA cross-reactive protein in E. coli cell lysates versus time of assay.
Each number represents the average of two determinations. The data for the His-426 peptide represent the average of three determinations: two from the specific activity of the wild-type peptide derived from the PA01 toxA gene and one from the specific activity of the Tyr-426-to-His revertant peptide.
c The specific ADP-ribosyltransferase activity of the His-426 fusion peptide as defined above was set as 100% activity.
ribosyltransferase activity of the mutant peptides examined. The specific activity of the H426P peptide was approximately 40,000 times less than that of the wild-type peptide (Table 3) .
We attempted to determine whether the H426n peptides were altered in their interaction with the reaction substrate NAD+ by measuring the kinetic properties of NAD-glycohydrolase activity of the peptides expressed in E. coli. Because of NAD-glycohydrolase activity endogenous to E. coli, NAD-glycohydrolase activity of the wild-type peptide expressed in this host was not detectable above the activity from E. coli harboring the vector alone. We attempted to separate the endogenous E. coli NAD-glycohydrolase activity from the activity expressed by the H426n peptides using sequential steps of gel filtration chromatography, anionexchange chromatography with step NaCl elution, and highpressure liquid chromatography-anion-exchange chromatography with linear NaCl elution. However, these methods proved unsuccessful in separating the E. coli NAD-glycohydrolase activity and enzymatic activity of the H426n peptides. Consequently, we constructed plasmids to encode the full-size 66,000-Da form of ETA containing either Ala-426 or Tyr-426 to purify these proteins from P. aeruginosa for further analysis.
Properties of H426n mutations in full-size ETA proteins. Figure 2 presents the cloning strategy used to construct pPEPH426A and pPEPH426Y into plasmids encoding the full-size form of ETA with Ala-426 or Tyr-426, respectively. The resultant plasmids, pTOXH426A and pTOXH426Y, contain a 2.4-kb DNA fragment encoding 66,000-Da ETA proteins. These plasmids also contain a broad-host-range origin of replication that allows stable replication in a P. aeruginosa host (15, 37) . We purified the full-size form of ETAH426A, which corresponds to the most active mutant peptide tested, the well-characterized ETAH426Y protein (CRM 66), and wild-type ETA for further analysis.
The ETA proteins were purified from P. aeruginosa culture supernatant by gel filtration and anion-exchange chromatographic methods. SDS migrating at 66,000 Da for each preparation (Fig. 4) . Purification of wild-type ETA and ETAH426Y resulted in preparations containing a single major protein (Fig. 4) . However, the presence of an -97-kDa protein was repeatedly observed in the NaCl-eluted fractions from the anion-exchange column when ETAH426A was purified ( Fig. 4A ; see Fig. 6 ). Repeated attempts to obtain a preparation of ETAH426A free from this contaminating protein proved unsuccessful. Western blot analysis of the ETAH426A preparation revealed that this 97-kDa protein does not cross-react with anti-ETA serum (Fig. 4B) . ADP-ribosyltransferase activity of wild-type ETA was enhanced eight to ten times by urea plus DTT preincubation, and the activity of ETAH426A was potentiated two to three times by urea plus DTT treatment (Table 4 ). In contrast, the ADP-ribosyltransferase activity of ETAH426Y was adversely affected by urea plus DTT treatment (Table 4) . Quantitation of ADP-ribosyltransferase activity by using the most active form of each purified full-size ETA preparation Expression of NAD-glycohydrolase activity of purified wild-type ETA required preincubation in urea plus DTT (Table 5 ). Neither ETAH426A nor ETAH426Y showed detectable NAD-glycohydrolase activity when treated in urea plus DTT. Optimal NAD-glycohydrolase activity for wild-type ETA was observed by treatment in 4 M urea plus 52 mM DTT and then incubation in reaction mixtures containing 52 mM 1n-mercaptoethanol. The rate of NADglycohydrolase activity of treated wild-type ETA was linear for approximately 1 h, after which the rate decreased with increased incubation (Fig. 5) . Attempts to extend the linearity of NAD-glycohydrolase activity versus time were unsuccessful. Incubation of treated wild-type ETA in reactions containing 0.1% Triton X-100, 0.1% CHAPS (3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate), or 156 mM 1-mercaptoethanol resulted in lower activity compared with the standard reaction and did not extend the linearity of activity versus time (data not shown). Also, preincubating wild-type ETA in 4 M urea plus 52 mM 3-mercaptoethanol (rather than urea plus DTT) did not enhance activity or extend the linearity of activity versus time (data not shown). Table 5 summarizes the results of quantitating NADglycohydrolase activity with the most active form of purified full-size wild-type ETA, ETAH426A, and ETAH426Y. Both ETAH426A and ETAH426Y were substantially reduced in NAD-glycohydrolase activity, retaining 0.9 and 0.4% of wild-type levels, respectively. Under the assay conditions employed, these activities were too low to allow evaluation of kinetic properties of the mutant proteins.
The differential response of the enzymatic activities of the three ETA proteins to treatment with urea plus DTT suggested that the conformations of these proteins differ. To address this more specifically, we determined the susceptibility of each toxin to limited digestion with trypsin. SDS-PAGE analysis of ETA peptides generated by time course trypsin digestion revealed that the three toxins have similar tryptic peptides as well as unique peptides (Fig. 6 ). Three groups of tryptic peptides with similar sizes were generated. One group that showed peptides with similar migration patterns appeared at approximately 60,000 Da. Each of the three ETA proteins was initially degraded through a peptide of approximately 58 kDa which accumulated with time (Fig.  6) . Two other groups, which migrated at approximately 45 and 30 kDa, exhibited peptides that were unique between the toxins (Fig. 6) . A major difference in the pattern of tryptic peptides generated is apparent when the peptides migrating in the -30-to 32-kDa range are examined. For wild-type ETA, a doublet migrating at 30 and 32 kDa appeared immediately after trypsin addition. The 30-kDa peptide disappeared after 5 min of digestion, and the 32-kDa peptide accumulated with time. For ETAH426Y, the 32-kDa peptide accumulated with approximately the same kinetics as with wild-type ETA. However, the 30-kDa peptide was present immediately after trypsin addition and persisted throughout the entire time course (Fig. 6) Fig. 6 revealed that the peptides generated by trypsin digestion react with ETA antiserum (data not shown). This demonstrates that the tryptic peptides result from proteolytic cleavage of ETA and are not contaminating peptides.
The presence of similar tryptic peptides suggests that overall, the three proteins possess similar protein conformation, while the presence of unique peptides is consistent with localized perturbation of protein structure. These data support the proposed structural differences between wild-type ETA, ETAH426A, and ETAH426Y based on the differential response of the enzymatic activities of each toxin to urea plus DTT treatment.
DISCUSSION
Previous analysis of CRM 66 suggested that substitution of Tyr for His-426 affected both ADP-ribosyltransferase activity and protein conformation (43 (Fig. 6 ) and data presented previously demonstrating that CRM 66 and wild-type ETA react differently to anti-ETA monoclonal antibodies (44) suggest these proteins have conformational differences. Thus, it appears that comparison of ADP-ribosyltransferase activity of carboxy-terminal peptides may more accurately reflect the effect of an amino acid substitution on enzymatic activity.
High levels of endogenous NAD-glycohydrolase activity present in partially purified preparations of H426n peptides prevented use of these peptides for determining the role of His-426 in NAD-glycohydrolase activity. We therefore quantitated this activity using purified full-size wild-type ETA, ETAH426A, and ETAH426Y. NAD-glycohydrolase activity of wild-type ETA is enhanced approximately 30 times with urea plus DTT preincubation, whereas NADglycohydrolase activity of both ETAH426A and ETAH426Y is adversely affected by urea plus DTT treatment. The observation that NAD-glycohydrolase activity of both mutant proteins is not potentiated by denaturation and reduction suggests that their NAD binding site is exposed and supports the proposed conformational differences between wild-type and mutant proteins. Alternatively, the inability to detect NAD-glycohydrolase activity in the treated form of either mutant toxin may be due to the fact that, although urea is required for activation of enzymatic activity, the presence of urea in the reaction interferes with detection of low levels of NAD-glycohydrolase activity.
Analysis of the most active form of ETAH426A and ETAH426Y revealed that both mutant proteins exhibit < 1% of wild-type levels of NAD-glycohydrolase activity. This is the first report demonstrating that substitution of His-426 results in an ETA protein with reduced NAD-glycohydrolase activity. However, the observation that the Tyr-426 and Ala-426 substitutions, when introduced into the full-size ETA protein, result in localized regions of conformational differences makes it difficult to accurately assess the contribution of the amino acid substitution to the reduction in NAD-glycohydrolase activity. To investigate the role of His-426 in the interaction with NAD, we attempted to experimentally determine the apparent Km for NAD for the wild-type and mutant ETA proteins. However, several factors made these determinations difficult. First, Fig. 5 shows that there was a very short period when NAD-glycohydrolase activity of treated wild-type ETA was proportional to time. The loss of linearity could be due to the accumulation of an inhibitory product or folding of the protein into an enzymatically inactive conformation. Second, we presented evidence demonstrating that the conformation of the three purified proteins differs, making the absolute contribution of the amino acid substitution on altered enzyme kinetics difficult to assess.
Substitution of Ala or Tyr for His-426 results in full-size ETA proteins that express reduced NAD-glycohydrolase activity and reduced ADP-ribosyltransferase activity. However, based on several criteria presented here and elsewhere (43, 44) , the full-size forms of wild-type ETA, ETAH426A, and ETAH426Y (CRM 66) exhibit conformational differences. This caveat must be considered when defining the precise role of His-426 in catalysis. For example, the proposed role of His-426 in the interaction between ETA and EF2 proposed by Galloway et al. (17) was based on data obtained from full-size ETA proteins. Our observation that ETAH426Y (CRM 66) does not require urea plus DTT treatment for expression of either ADP-ribosyltransferase activity or NAD-glycohydrolase activity suggests that the NAD-binding site in CRM 66 is exposed. An exposed NAD-binding site in CRM 66 may explain the apparent wild-type NAD-binding property previously reported for CRM 66 (17) , which led these investigators to propose that His-426 interacts with EF2. Other studies of NAD binding to wild-type ETA have been reported by crystallographic localization of bound NAD fragments (4) or photoaffinity labeling of an ETA peptide (6) . Use of these methodologies to analyze NAD binding by CRM 66 or the H426Y peptide may allow the effect of the His-426-to-Tyr mutation on NAD binding to be directly assessed and may allow definition of the role of His-426 in substrate interaction.
Reduced ADP-ribosyltransferase activity detected by analysis of carboxy-terminal H426n peptides, which exhibit no apparent conformational differences, suggests that His-426 has a role in the enzymatic activity of ETA. These data, however, do not provide evidence for a direct catalytic role of His-426 in the enzymatic activity of ETA. A likely explanation is that this residue plays an important structural role in the molecular architecture of the catalytic center of ETA. Interestingly, the molecular model of ETA reveals that His-426 does not extend into the identified cleft (1), and computer modelling studies do not implicate His-426 as an active-site residue (4, 13) . However, it is important to note that the molecular structure of ETA and the proposed models for NAD binding were built based on data obtained from crystallographic analysis of the enzymatically inactive ETA proenzyme. The proximity of His-426 to catalytically important residues in the enzymatically active form of ETA is not known. His-426 may influence the binding of EF2 or NAD+ in the catalytic pocket of the enzyme and may be critical in properly orienting active-site residues within the cleft. The dramatic reduction in enzymatic activity observed with the Pro-426 substitution provides support for the hypothesis that movement around His-426 is an important factor in catalytic function of ETA. 
